FDA requesting more studies for Vertex's deuterated ivacaftor

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said FDA requested additional dose-finding studies, which could include monotherapy evaluation, of cystic fibrosis candidate VX-561 before the company brings it into late-stage development as part of

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE